Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating) have earned a consensus rating of “Buy” from the seven brokerages that are presently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have updated their coverage on the stock […]
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating) – Equities research analysts at SVB Leerink raised their Q2 2023 earnings per share estimates for shares of Mersana Therapeutics in a research note issued on Tuesday, May 9th. SVB Leerink analyst J. Chang now forecasts that the company will post earnings per share of ($0.48) for the […]
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating) – Equities researchers at Wedbush reduced their Q2 2023 EPS estimates for Mersana Therapeutics in a research report issued on Tuesday, May 9th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.53) per share for the quarter, down from their previous forecast of ($0.49). The […]
Mersana Therapeutics (NASDAQ:MRSN – Get Rating) released its quarterly earnings data on Tuesday. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.11), Briefing.com reports. The firm had revenue of $7.80 million for the quarter, compared to the consensus estimate of $18.29 million. Mersana Therapeutics had a […]
Mersana Therapeutics (NASDAQ:MRSN – Get Rating) issued its quarterly earnings results on Tuesday. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.11), Briefing.com reports. Mersana Therapeutics had a negative net margin of 768.26% and a negative return on equity of 178.80%. The company had revenue of […]